cisplatin + fluorouracil + afatinib

Cisplatin + fluorouracil + afatinib is a combination regimen of three anticancer drugs used primarily in clinical research for the treatment of advanced gastric and gastroesophageal junction cancers. Cisplatin is a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. Fluorouracil (also known as 5-fluorouracil or 5FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. Afatinib is an irreversible small molecule tyrosine kinase inhibitor targeting the ErbB family (including Epidermal growth factor receptor (EGFR), Human epidermal growth factor receptor 2 (HER2), and Human epidermal growth factor receptor 4 (HER4)), blocking downstream signaling pathways involved in cell proliferation and survival. This combination aims to enhance antitumor efficacy by integrating cytotoxic chemotherapy with targeted inhibition of growth factor signaling[1][2][3].

Brand names

Gilotrif + cisplatin + 5-fluorouracil

Other names

cisplatin5-fluorouracil5FUafatinib